Fresenius Medical Care AG
FMS NYSE· Services-Misc Health & Allied Services, Nec
Last close · Oct 30, 2026
$22.47
KIRA · Stoqly’s AI analyst, in plain words
- Fresenius Medical Care AG had $22.1B of revenue in fiscal 2025, up 5.8% on the year before. Over five years, revenue changed +1.7% a year on average.
- Its operating margin was 9.3%, up 2.1 pts: of every 100 in sales, about 9 is left after running the business.
- Fresenius Medical Care AG made $1.1B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −0.9% a year.
- Fresenius Medical Care AG returned $1.1B to shareholders in fiscal 2025. The diluted share count fell 0.8%.
- Fresenius Medical Care AG owes $10.8B more than it holds in cash, about 2.9 years of operating profit.
Market cap
$6.5B
P/E
5.9x
Revenue
$22.1B
Net income
$1.1B
Free cash flow
—
Operating margin
9.3%
Fresenius Medical Care AG in 30 seconds · fiscal 2025
Are sales growing?
+5.8%
Yes. Sales grew 5.8% last year.
Does it make a profit?
5.0%
A little. It keeps 5.0% of every sale as profit.
Is debt under control?
2.9x
Keep an eye on it. Repaying its debt would take 2.9 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
5.9x
One share costs 5.9 times its yearly profit per share.
What Fresenius Medical Care AG does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 24, 2026
- Legal name
- Fresenius Medical Care AG
- CIK
- 0001333141
Fresenius Medical Care AG · FMS · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $20.8B | $20.4B | $21.0B | $20.9B | $22.1B |
| Revenue growth | 2.4% | −2.2% | 3.2% | −0.6% | 5.8% |
| Net interest income | −$332M | −$307M | −$364M | −$363M | −$355M |
| Gross margin | 28.8% | 27.4% | 25.3% | 24.6% | 25.6% |
| Operating margin | 10.5% | 7.8% | 7.0% | 7.2% | 9.3% |
| Net income | $1.1B | $708M | $540M | $582M | $1.1B |
| Net margin | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| Diluted EPS | $3.91 | $2.42 | $1.84 | $1.98 | $3.79 |
| Cash | |||||
| Cash from operations | $2.9B | $2.3B | $2.8B | $2.6B | $3.0B |
| Dividends paid | $464M | $416M | $355M | $378M | $476M |
| Share buybacks | — | — | — | — | $660M |
| Share count change | −0.4% | 0.1% | 0.1% | 0.0% | −0.8% |
| Debt and strength | |||||
| Cash and short-term investments | $1.7B | $1.4B | $1.6B | $1.2B | $1.9B |
| Debt incl. finance leases | $15.1B | $14.1B | $13.5B | $11.4B | $12.7B |
| Shareholders' equity | $14.4B | $14.9B | $15.1B | $15.1B | $15.6B |
| Net debt / EBITDA | 3.3x | 3.7x | 3.7x | 3.2x | 2.9x |
| Current ratio | 1.1x | 1.3x | 1.4x | 1.4x | 1.3x |
| Interest coverage | 5.4x | 4.2x | 3.3x | 3.5x | 4.9x |
| Returns and quality | |||||
| Return on capital | 6.1% | 4.2% | 3.9% | 4.2% | 6.1% |
| Return on equity | 8.1% | 4.8% | 3.6% | 3.9% | 7.2% |
| Piotroski F-score | 6 | 5 | 6 | 7 | 7 |
| Altman Z'' | 2.2 | 2.3 | 2.6 | 2.7 | 2.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fresenius Medical Care AG · FMS · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $22.47 a share, the company is worth $6.5B: 5.9 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001333141). Latest version: stoqly.net/companies/fms. Data updated November 1, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.